Pax8 modulates the expression of Wnt4 that is necessary for the maintenance of the epithelial phenotype of thyroid cells

BMC Molecular Biology

Mariastella Zannini¹  Valeria Lucci¹  Tina Di Palma¹  Maria Grazia Filippone¹ 

[1] IEOS - Institute of Experimental Endocrinology and Oncology CNR - National Research Council, via S. Pansini 5, 80131 Naples, Italy

关键词: Thyroid cancer;    Mesenchyme-to-epithelium transition;    Transcriptional regulation;    Pax8;    Wnt4;   

Others  :  1090266
DOI  :  10.1186/1471-2199-15-21

 received in 2014-04-17, accepted in 2014-09-23,  发布年份 2014

【 摘 要 】

Background

The transcription factor Pax8 is expressed during thyroid development and is involved in the morphogenesis of the thyroid gland and maintenance of the differentiated phenotype. In particular, Pax8 has been shown to regulate genes that are considered markers of thyroid differentiation. Recently, the analysis of the gene expression profile of FRTL-5 differentiated thyroid cells after the silencing of Pax8 identified Wnt4 as a novel target. Like the other members of the Wnt family, Wnt4 has been implicated in several developmental processes including regulation of cell fate and patterning during embryogenesis. To date, the only evidence on Wnt4 in thyroid concerns its down-regulation necessary for the progression of thyroid epithelial tumors.

Results

Here we demonstrate that Pax8 is involved in the transcriptional modulation of Wnt4 gene expression directly binding to its 5’-flanking region, and that Wnt4 expression in FRTL-5 cells is TSH-dependent. Interestingly, we also show that in thyroid cells a reduced expression of Wnt4 correlates with the alteration of the epithelial phenotype and that the overexpression of Wnt4 in thyroid cancer cells is able to inhibit cellular migration.

Conclusions

We have identified and characterized a functional Pax8 binding site in the 5’-flanking region of the Wnt4 gene and we show that Pax8 modulates the expression of Wnt4 in thyroid cells. Taken together, our results suggest that in thyroid cells Wnt4 expression correlates with the integrity of the epithelial phenotype and is reduced when this integrity is perturbed. In the end, we would like to suggest that the overexpression of Wnt4 in thyroid cancer cells is able to revert the mesenchymal phenotype.

【 授权许可】

   
2014 Filippone et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Nelson WJ, Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303(5663):1483-1487.
• [2]Eisenmann DM: Wnt Signaling. In WormBook: The Online Review of C Elegans Biology 2005, 25:1-17.
• [3]Li Q, Kannan A, Das A, Demayo FJ, Hornsby PJ, Young SL, Taylor RN, Bagchi MK, Bagchi IC: WNT4 acts downstream of BMP2 and functions via beta-catenin signaling pathway to regulate human endometrial stromal cell differentiation. Endocrinology 2013, 154(1):446-457.
• [4]Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP, Weinberg RA: Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 2000, 14(6):650-654.
• [5]Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP: Female development in mammals is regulated by Wnt-4 signalling. Nature 1999, 397(6718):405-409.
• [6]Stark K, Vainio S, Vassileva G, McMahon AP: Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 1994, 372(6507):679-683.
• [7]Tanigawa S, Wang H, Yang Y, Sharma N, Tarasova N, Ajima R, Yamaguchi TP, Rodriguez LG, Perantoni AO: Wnt4 induces nephronic tubules in metanephric mesenchyme by a non-canonical mechanism. Dev Biol 2011, 352(1):58-69.
• [8]Torban E, Dziarmaga A, Iglesias D, Chu LL, Vassilieva T, Little M, Eccles M, Discenza M, Pelletier J, Goodyer P: PAX2 activates WNT4 expression during mammalian kidney development. J Biol Chem 2006, 281(18):12705-12712.
• [9]Biason-Lauber A, De Filippo G, Konrad D, Scarano G, Nazzaro A, Schoenle EJ: WNT4 deficiency–a clinical phenotype distinct from the classic Mayer-Rokitansky-Kuster-Hauser syndrome: a case report. Hum Reprod 2007, 22(1):224-229.
• [10]Mandel H, Shemer R, Borochowitz ZU, Okopnik M, Knopf C, Indelman M, Drugan A, Tiosano D, Gershoni-Baruch R, Choder M, Sprecher E: SERKAL syndrome: an autosomal-recessive disorder caused by a loss-of-function mutation in WNT4. Am J Hum Genet 2008, 82(1):39-47.
• [11]Philibert P, Biason-Lauber A, Rouzier R, Pienkowski C, Paris F, Konrad D, Schoenle E, Sultan C: Identification and functional analysis of a new WNT4 gene mutation among 28 adolescent girls with primary amenorrhea and mullerian duct abnormalities: a French collaborative study. J Clin Endocrinol Metab 2008, 93(3):895-900.
• [12]De Menna M, D’Amato V, Ferraro A, Fusco A, Di Lauro R, Garbi C, De Vita G: Wnt4 inhibits cell motility induced by oncogenic Ras. Oncogene 2013, 32(35):4110-4119.
• [13]Di Palma T, Conti A, de Cristofaro T, Scala S, Nitsch L, Zannini M: Identification of novel Pax8 targets in FRTL-5 thyroid cells by gene silencing and expression microarray analysis. PLoS One 2011, 6(9):e25162.
• [14]Mansouri A, Chowdhury K, Gruss P: Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet 1998, 19(1):87-90.
• [15]Pasca di Magliano M, Di Lauro R, Zannini M: Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci U S A 2000, 97(24):13144-13149.
• [16]Di Palma T, Zampella E, Filippone MG, Macchia PE, Ris-Stalpers C, de Vroede M, Zannini M: Characterization of a novel loss-of-function mutation of PAX8 associated with congenital hypothyroidism. Clin Endocrinol (Oxf) 2010, 73(6):808-814.
• [17]Macchia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L, Souabni A, Baserga M, Tassi V, Pinchera A, Fenzi G, Grueters A, Busslinger M, Di Lauro R: PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998, 19(1):83-86.
• [18]Al Taji E, Biebermann H, Limanova Z, Hnikova O, Zikmund J, Dame C, Gruters A, Lebl J, Krude H: Screening for mutations in transcription factors in a Czech cohort of 170 patients with congenital and early-onset hypothyroidism: identification of a novel PAX8 mutation in dominantly inherited early-onset non-autoimmune hypothyroidism. Eur J Endocrinol/ Eur Fed Endocr Societies 2007, 156(5):521-529.
• [19]Narumi S, Muroya K, Asakura Y, Adachi M, Hasegawa T: Transcription factor mutations and congenital hypothyroidism: systematic genetic screening of a population-based cohort of Japanese patients. J Clin Endocrinol Metab 2010, 95(4):1981-1985.
• [20]Bouchard M, Souabni A, Mandler M, Neubuser A, Busslinger M: Nephric lineage specification by Pax2 and Pax8. Genes Dev 2002, 16(22):2958-2970.
• [21]Plachov D, Chowdhury K, Walther C, Simon D, Guenet JL, Gruss P: Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development 1990, 110(2):643-651.
• [22]Christ S, Biebel UW, Hoidis S, Friedrichsen S, Bauer K, Smolders JW: Hearing loss in athyroid pax8 knockout mice and effects of thyroxine substitution. Audiol Neurootol 2004, 9(2):88-106.
• [23]Friedrichsen S, Christ S, Heuer H, Schafer MK, Parlow AF, Visser TJ, Bauer K: Expression of pituitary hormones in the Pax8-/- mouse model of congenital hypothyroidism. Endocrinology 2004, 145(3):1276-1283.
• [24]Wistuba J, Mittag J, Luetjens CM, Cooper TG, Yeung CH, Nieschlag E, Bauer K: Male congenital hypothyroid Pax8-/- mice are infertile despite adequate treatment with thyroid hormone. J Endocrinol 2007, 192(1):99-109.
• [25]Mittag J, Winterhager E, Bauer K, Grummer R: Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007, 148(2):719-725.
• [26]Mascia A, Nitsch L, Di Lauro R, Zannini M: Hormonal control of the transcription factor Pax8 and its role in the regulation of thyroglobulin gene expression in thyroid cells. J Endocrinol 2002, 172(1):163-176.
• [27]Bradley RS, Brown AM: The proto-oncogene int-1 encodes a secreted protein associated with the extracellular matrix. EMBO J 1990, 9(5):1569-1575.
• [28]Miller JR: The Wnts. Genome Biol 2002, 3(1):REVIEWS300.
• [29]Reichsman F, Smith L, Cumberledge S: Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction. J Cell Biol 1996, 135(3):819-827.
• [30]Damante G, Tell G, Di Lauro R: A unique combination of transcription factors controls differentiation of thyroid cells. Prog Nucleic Acid Res Mol Biol 2001, 66:307-356.
• [31]Parlato R, Rosica A, Rodriguez-Mallon A, Affuso A, Postiglione MP, Arra C, Mansouri A, Kimura S, Di Lauro R, De Felice M: An integrated regulatory network controlling survival and migration in thyroid organogenesis. Dev Biol 2004, 276(2):464-475.
• [32]Di Lauro R, Damante G, De Felice M, Arnone MI, Sato K, Lonigro R, Zannini M: Molecular events in the differentiation of the thyroid gland. J Endocrinol Invest 1995, 18(2):117-119.
• [33]Montanelli L, Tonacchera M: Genetics and phenomics of hypothyroidism and thyroid dys- and agenesis due to PAX8 and TTF1 mutations. Mol Cell Endocrinol 2010, 322(1–2):64-71.
• [34]Narlis M, Grote D, Gaitan Y, Boualia SK, Bouchard M: Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J Am Soc Nephrol 2007, 18(4):1121-1129.
• [35]Dumont JE, Lamy F, Roger P, Maenhaut C: Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992, 72(3):667-697.
• [36]Larsson F, Fagman H, Nilsson M: TSH receptor signaling via cyclic AMP inhibits cell surface degradation and internalization of E-cadherin in pig thyroid epithelium. Cell Mol Life Sci 2004, 61(14):1834-1842.
• [37]Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ: Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999, 13(17):2207-2217.
• [38]Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA: Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004, 18(10):1131-1143.
• [39]Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G: Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994, 54(17):4744-4749.
• [40]Lucci V, Di Palma T, D’Ambrosio C, Scaloni A, Zannini M: AMOTL2 interaction with TAZ causes the inhibition of surfactant proteins expression in lung cells. Gene 2013, 529(2):300-306.
• [41]Zannini M, Francis-Lang H, Plachov D, Di Lauro R: Pax-8, a paired domain-containing protein, binds to a sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters. Mol Cell Biol 1992, 12(9):4230-4241.
• [42]Ambesi-Impiombato FS, Coon HG: Thyroid cells in culture. Int Rev Cytol Suppl 1979, 10:163-172.
• [43]de Cristofaro T, Di Palma T, Fichera I, Lucci V, Parrillo L, De Felice M, Zannini M: An essential role for Pax8 in the transcriptional regulation of cadherin-16 in thyroid cells. Mol Endocrinol 2012, 26(1):67-78.
• [44]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.